(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
In Harch of 1980, we organized the first symposium on how to evaluate new antiarrhythmic agents in which the participants included members of the Cardio-Renal Division of the Food and Drug Administration, academic investigators from the United States and Abroad and directors and imple mentors of pharmacological research representing the pharmaceutical industry. By bringing together all three elements, it was hoped that better communication and under standing would ensue to more rapidly bring new cardiac agents to the American public. This goal was important since a rather limited number of antiarrhythmic agents were and are currently available to treat patients with such disorders in the United States. These agents are needed not only for the treatment of patients with sustained ventricular tachyarrhythmias which produce life-threatening hemodynamic consequences but also and in fact more potentially important as a prophylactic measure in the high risk patient subject to sudden cardiac death. This book represents the proceedings of the third of these Symposiums whose purpose was to evaluate the clinical research methodology and models used in the evaluation of ne" antiarrhythmic agents for not only acute therapeutic inter vention but also for the prophylaxis of sudden cardiac death. In addition, new devices have evolved over the past few years that can detect and treat life-threatening cardiac arrhythmias and the evaluation of efficacy and safety of these devices is detailed.
Contents:
New Antiarrhythmic Agents: Basic Considerations.- Do animal models predict results in man?.- Application of pharmacologic principles in the evaluation of new antiarrhythmic agents.- Characterization of antiarrhythmic drugs.- Panel Discussion: New antiarrhythmic agents: basic considerations.- Efficacy Models For Patients With Chronic Ventricular Arrhythmias.- How should ventricular arrhythmias be classified and which patients should be treated?.- Study design for patients with chronic ventricular ectopy: determination of efficacy and tolerance.- Chronic tolerance to antiarrhythmic therapy How to handle emergency drug requests.- Panel Discussion: Efficacy models for patients with chronic ventricular arrhythmias.- Efficacy Models: Acute Ventricular Arrhythmias.- The value of electrophysiologic testing in predicting long-term efficacy of antiarrhythmic drugs in patients with life-threatening ventricular arrhythmias.- Efficacy models: acute ventricular arrhythmias.- A look to the future: outpatient placebo controlled trials of antiarrhythmic drug efficacy in patients with life-threatening ventricular arrhythmias.- Panel Discussion: Efficacy models: acute ventricular arrhythmias.- Sudden Death: Can it Now be Used as an Endpoint?.- Protocol design for sudden death prevention.- Do beta blockers prevent sudden cardiac death?.- Does non beta-blocking antiarrhythmic therapy prevent sudden cardiac death?.- Current problems in the evaluation and approval of new antiarrhythmic agents.- Panel Discussion: Sudden death: can it now be used as an endpoint?.- New Devices: Pacemakers in the Treatment of Arrhythmias and Prevention of Sudden Cardiac Death.- New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- Transvenous cardioversion to treat tachyarrhythmias.- The role of permanently implanted pacemakers in the therapy of recurrent tachyarrhythmias.- Clinical evaluation of an implantable automatic cardioverter defibrillator.- Evaluation of devices for the prevention of sudden death: study design for safety and efficacy of the devices.- New device approval by the Food and Drug Administration.- Panel Discussion: New devices: pacemakers in the treatment of arrhythmias and prevention of sudden cardiac death.- New Cardiac Inotropic Agents.- Pharmacologic principles in the use of new inotropic agents.- The clinical assessment of A inotropic drugs.- Panel Discussion: New cardiac inotropic agents.- Conclusion: Remarks by Arthur Hull Hayes, Jr., Commissioner of Food and Drugs.- List of Participants.
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: October, 2011
Pages: 302
Weight: 498g
Availability: Available
Subcategories: Cardiovascular Medicine
From the same series
Jean-Claude Tardif
Xander H T Wehrens
Johan H. C. Reiber
Raimund Erbel
M.P. Sambhi
Pedro Brugada
W. Bleifeld
Naranjan S. Dhalla
Bohuslav Ostadal
Ralph Shabetai
Jason X.-J. Yuan
Hein J.J. Wellens
R. C. Becker
Franz H. Messerli
C.H. Peels
Stephen M. Factor
Hiroyuki Suga
Hugo Ector
Brian E. Jaski
Richard A. Walsh
Seymour Glagov
Michiel J. Janse
Lloyd W. Klein
Thomas H Marwick
Ernst E. van der Wall
P.J. Walter
Ernst E. van der Wall
Ernst E. van der Wall
A-M. Salmasi
Michel Emile Safar
A-M. Salmasi
Ernst E. van der Wall
Andrea Natale
Albert de Roos
C.A. Nienaber
Guillem Pons-Llado
Vinzenz Hombach
R. Vos
J. Candell-Riera
R.W. Stout
Peter Hanrath
Johan H. C. Reiber
P.A.F.M. Doevendans
Jack Rychik
P.A.F.M. Doevendans
P.E. Vardas
Makoto Nagano
George D. Dangas
Myrvin H. Ellestad
C.J. Preusse
Thomas H Marwick
Thomas H Marwick
Ernst E. van der Wall
G.T. Meester
A.G. Herman
J.C. Tardif
P.J. Walter
Johan H. C. Reiber
Ernst E. van der Wall
Lloyd W. Klein
Akira Matsumori
Robert L. Wilensky
Bernard Swynghedauw
Juan Carlos Kaski
Franz H. Messerli
John F. Keaney Jr.
Keith L. March
Naranjan S. Dhalla
Zainul Abedin
Juan Carlos Kaski
Eric J Topol
A.V. Bruschke
Richard C. Becker
J. Candell-Riera
Ghassan Bkaily
Lionel H. Opie
Bernard Swynghedauw
Geoffrey Burnstock
P. Cummins
Nicholas Sperelakis
Mina Rajskina
A.A. Knowlton
Johan H. C. Reiber
Irene D. Turpie
J. A. E. Spaan
Ernst E. van der Wall
Masatsugu Hori
Bing Liem Liong
R. Fagard
M. Iwase
R. Stroobandt
A.V. Bruschke
David M. Mirvis
Franz H. Messerli
G. Assmann
Melvin Scheinman
J. Morganroth
J.W. de Jong
M.B. Rosenbaum
C. Tissa Kappagoda
H.V. Villareal
J. Morganroth
Ernst E. van der Wall
Naranjan S. Dhalla
H. Mitchell Perry Jr.
M.P. Spencer
Henk Keurs
C.T. Lancée
J.R. Roelandt
G.S. Wagner
H. Kesteloot
A.C. Arntzenius
Johan H. C. Reiber
A. Maseri
Michel Emile Safar
M.P. Spencer
W. Bleifeld
Henk Keurs
Willem H. Birkenhager
Antonio Bayes de Luna
J.R. Roelandt
Naranjan S. Dhalla
H. Rijsterborgh
Marianne J. Legato
Naranjan S. Dhalla
S. Chien
Rafael Beyar
H.E. Van Dam
M.P. Spencer
J.R. Roelandt
Hilbert J.Th. Thalen
C. Marchesi
J.P.M Hamer
Rafael Beyar
L.N. Bouman
A. Alboni
Douglas P. Zipes
Nicholas Sperelakis
Borys Surawicz
Antonio Bayes de Luna
Johan H. C. Reiber
Hein J.J. Wellens
J.V. Chapman
E. Aliot
Vinzenz Hombach
Michael R. Rosen
William H. Gaasch
Pawan K. Singal
Robert Plonsey
H.L. Stone
J. Soler-Soler
Ernst E. van der Wall
Michel Emile Safar
J. Morganroth
Hein J.J. Wellens
J.R. Roelandt
Vinzenz Hombach
Richard S. Meltzer
Marvin A. Konstam
Naranjan S. Dhalla
Naranjan S. Dhalla
S.N. Willich
Johan H. C. Reiber
C.A. Nienaber
Ernst E. van der Wall
Robert J. Siegel
Markus Schwaiger
Andrew Wechsler
Elliot Rapaport
Naranjan S. Dhalla
John E. Tooke
Derek Yellon
Henk Keurs
Steve M. Teague
J.W. de Jong
Naranjan S. Dhalla
Nicholas Sperelakis
P.H. Heintzen
J. Morganroth
John B. Lombardini
Adam Schneeweiss
J.R. Roelandt
Naranjan S. Dhalla
Naranjan S. Dhalla
J.C. Chatham
Pim J. de Feyter
David W. Holt
Catherine A. Neill
J. Roelandt
A.P. Shepherd
Gastone Leonetti
Nico H.J. Pijls
K. Robinson
P.A.F.M. Doevendans
Douglas P. Zipes
Jose Marin-Garcia
Jonathan S. Steinberg
Francisco Villarreal
Dick Macdonald
Ragavendra R. Baliga
Dick Macdonald